一表读懂!厄贝沙坦、氯沙坦、缬沙坦……ARB 类药物超说明书用药!

2022-08-16 MedSci原创 MedSci原创 发表于上海

干货满满~

2022628,广东省药学会发布了《超药品说明书用药目录(2022年版)》,共计269个超药品说明书用法。其中血管紧张素 II 受体阻滞剂(ARB)也在其中,为了便于大家阅读参考,梅斯医学为您整理成表格,以便同道收藏。

参考资料

超药品说明书用药目录(2022年版).广东省药学会. 20226

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1654126, encodeId=5453165412638, content=<a href='/topic/show?id=480192929b3' target=_blank style='color:#2F92EE;'>#超说明书用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92929, encryptionId=480192929b3, topicName=超说明书用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b24449208, createdName=marlenexl, createdTime=Thu Apr 20 23:06:46 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992960, encodeId=d1b61992960a5, content=<a href='/topic/show?id=72d29292681' target=_blank style='color:#2F92EE;'>#超说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92926, encryptionId=72d29292681, topicName=超说明书)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Jul 23 12:06:46 CST 2023, time=2023-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700942, encodeId=64f21e0094290, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eef30296447, createdName=listen328, createdTime=Thu Jun 22 07:06:46 CST 2023, time=2023-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367702, encodeId=05f3136e702ff, content=<a href='/topic/show?id=9334e9305c7' target=_blank style='color:#2F92EE;'>#缬沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79305, encryptionId=9334e9305c7, topicName=缬沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Thu Aug 18 08:06:46 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507230, encodeId=de0b150e230f6, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Thu Aug 18 08:06:46 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239185, encodeId=90a6123918559, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=703a1476598, createdName=dr.huangping, createdTime=Wed Aug 17 06:21:27 CST 2022, time=2022-08-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1654126, encodeId=5453165412638, content=<a href='/topic/show?id=480192929b3' target=_blank style='color:#2F92EE;'>#超说明书用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92929, encryptionId=480192929b3, topicName=超说明书用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b24449208, createdName=marlenexl, createdTime=Thu Apr 20 23:06:46 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992960, encodeId=d1b61992960a5, content=<a href='/topic/show?id=72d29292681' target=_blank style='color:#2F92EE;'>#超说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92926, encryptionId=72d29292681, topicName=超说明书)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Jul 23 12:06:46 CST 2023, time=2023-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700942, encodeId=64f21e0094290, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eef30296447, createdName=listen328, createdTime=Thu Jun 22 07:06:46 CST 2023, time=2023-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367702, encodeId=05f3136e702ff, content=<a href='/topic/show?id=9334e9305c7' target=_blank style='color:#2F92EE;'>#缬沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79305, encryptionId=9334e9305c7, topicName=缬沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Thu Aug 18 08:06:46 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507230, encodeId=de0b150e230f6, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Thu Aug 18 08:06:46 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239185, encodeId=90a6123918559, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=703a1476598, createdName=dr.huangping, createdTime=Wed Aug 17 06:21:27 CST 2022, time=2022-08-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1654126, encodeId=5453165412638, content=<a href='/topic/show?id=480192929b3' target=_blank style='color:#2F92EE;'>#超说明书用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92929, encryptionId=480192929b3, topicName=超说明书用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b24449208, createdName=marlenexl, createdTime=Thu Apr 20 23:06:46 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992960, encodeId=d1b61992960a5, content=<a href='/topic/show?id=72d29292681' target=_blank style='color:#2F92EE;'>#超说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92926, encryptionId=72d29292681, topicName=超说明书)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Jul 23 12:06:46 CST 2023, time=2023-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700942, encodeId=64f21e0094290, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eef30296447, createdName=listen328, createdTime=Thu Jun 22 07:06:46 CST 2023, time=2023-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367702, encodeId=05f3136e702ff, content=<a href='/topic/show?id=9334e9305c7' target=_blank style='color:#2F92EE;'>#缬沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79305, encryptionId=9334e9305c7, topicName=缬沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Thu Aug 18 08:06:46 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507230, encodeId=de0b150e230f6, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Thu Aug 18 08:06:46 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239185, encodeId=90a6123918559, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=703a1476598, createdName=dr.huangping, createdTime=Wed Aug 17 06:21:27 CST 2022, time=2022-08-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1654126, encodeId=5453165412638, content=<a href='/topic/show?id=480192929b3' target=_blank style='color:#2F92EE;'>#超说明书用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92929, encryptionId=480192929b3, topicName=超说明书用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b24449208, createdName=marlenexl, createdTime=Thu Apr 20 23:06:46 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992960, encodeId=d1b61992960a5, content=<a href='/topic/show?id=72d29292681' target=_blank style='color:#2F92EE;'>#超说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92926, encryptionId=72d29292681, topicName=超说明书)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Jul 23 12:06:46 CST 2023, time=2023-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700942, encodeId=64f21e0094290, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eef30296447, createdName=listen328, createdTime=Thu Jun 22 07:06:46 CST 2023, time=2023-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367702, encodeId=05f3136e702ff, content=<a href='/topic/show?id=9334e9305c7' target=_blank style='color:#2F92EE;'>#缬沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79305, encryptionId=9334e9305c7, topicName=缬沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Thu Aug 18 08:06:46 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507230, encodeId=de0b150e230f6, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Thu Aug 18 08:06:46 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239185, encodeId=90a6123918559, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=703a1476598, createdName=dr.huangping, createdTime=Wed Aug 17 06:21:27 CST 2022, time=2022-08-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1654126, encodeId=5453165412638, content=<a href='/topic/show?id=480192929b3' target=_blank style='color:#2F92EE;'>#超说明书用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92929, encryptionId=480192929b3, topicName=超说明书用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b24449208, createdName=marlenexl, createdTime=Thu Apr 20 23:06:46 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992960, encodeId=d1b61992960a5, content=<a href='/topic/show?id=72d29292681' target=_blank style='color:#2F92EE;'>#超说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92926, encryptionId=72d29292681, topicName=超说明书)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Jul 23 12:06:46 CST 2023, time=2023-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700942, encodeId=64f21e0094290, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eef30296447, createdName=listen328, createdTime=Thu Jun 22 07:06:46 CST 2023, time=2023-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367702, encodeId=05f3136e702ff, content=<a href='/topic/show?id=9334e9305c7' target=_blank style='color:#2F92EE;'>#缬沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79305, encryptionId=9334e9305c7, topicName=缬沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Thu Aug 18 08:06:46 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507230, encodeId=de0b150e230f6, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Thu Aug 18 08:06:46 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239185, encodeId=90a6123918559, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=703a1476598, createdName=dr.huangping, createdTime=Wed Aug 17 06:21:27 CST 2022, time=2022-08-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1654126, encodeId=5453165412638, content=<a href='/topic/show?id=480192929b3' target=_blank style='color:#2F92EE;'>#超说明书用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92929, encryptionId=480192929b3, topicName=超说明书用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b24449208, createdName=marlenexl, createdTime=Thu Apr 20 23:06:46 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992960, encodeId=d1b61992960a5, content=<a href='/topic/show?id=72d29292681' target=_blank style='color:#2F92EE;'>#超说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92926, encryptionId=72d29292681, topicName=超说明书)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Jul 23 12:06:46 CST 2023, time=2023-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700942, encodeId=64f21e0094290, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eef30296447, createdName=listen328, createdTime=Thu Jun 22 07:06:46 CST 2023, time=2023-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367702, encodeId=05f3136e702ff, content=<a href='/topic/show?id=9334e9305c7' target=_blank style='color:#2F92EE;'>#缬沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79305, encryptionId=9334e9305c7, topicName=缬沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Thu Aug 18 08:06:46 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507230, encodeId=de0b150e230f6, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Thu Aug 18 08:06:46 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239185, encodeId=90a6123918559, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=703a1476598, createdName=dr.huangping, createdTime=Wed Aug 17 06:21:27 CST 2022, time=2022-08-17, status=1, ipAttribution=)]
    2022-08-17 dr.huangping

    学习了

    0

相关资讯

安罗替尼超说明书用药知多少?专家共识告诉你

安罗替尼在临床超说明书用药普遍存在。

女婴服用“PDE5抑制剂”遭吐槽 超说明书用药缺乏“国标”

日前,一则“女婴服用‘伟哥’”的新闻引发关注。医生解释这属于正常情况的同时,网友们纷纷吐槽“是不是搞错了”。事实上,这种情况并非孤例,超说明书用药在我国较为普遍。医学专家表示,由于没有统一的规范和标准,医生超说明书用药时要面临较大的法律风险,同时也容易导致患者对医生、药品的不信任。超说明书用药不是新鲜事 儿童用药常与年龄规定不相符  在我国,超说明书用药一般指4种情况,说明书未提及特殊人群(如妊娠

新鲜整理!2022年风湿领域超说明用药目录

新鲜整理!2022年风湿领域超说明用药目录。

张煜再次炮轰陆巍「五药联合」完全错误!超说明书用药风险几何?

超说明书用药相对仍具有较高风险,十分考验临床医生的专业水平。在法律保护下,严格遵守用药原则,充分进行医患沟通,严密进行病情监测是使“超说明书用药”长久焕发活力的最终保证。

关于超说明书用药,医生一定要了解这些!

超说明书用药具有其合理性与必要性。